Instead of using a microplate, you c

an easily establish your own ELISA (competitive or Sandwich ELISA) by using your antibodies and antigens on the BioTeZ Low Density Biochip.

Assay scheme:

1. Competitive ELISA

Basic LD Biochip (Kit) | antibody or antiserum | antigen + antigen-HRP | TMB (Kit)

2. Sandwich ELISA

Streptavidin LD Biochip (Kit)| biotinylated capture antibody | antigen + signal antibody-HRP | TMB (Kit)

To run the immunoassay, you need:

  • our Kit but your own antigen, antibodies and HRP-conjugates
  • vortex-mixer, micropipette or micro-multipette (1–10µl), spray bottle (for washing)
  • box for microscopy slides (for humid incubation)
  • Optical device with a digital camera and software

Kit content:

  • 10 Basic LD Biochips for biotinylated antibodies
  • 10 Streptavidin LD Biochips for non-biotinylated antibodies
  • 1 vial TMB solution [precipitating substrate solution], ready-to-use

further details: LD BioScreen Sandwich ELISA D.pdf
further details: LD BioScreen kompetitiver ELISA.pdf

BioTeZ GmbH

Die BioTeZ Berlin-Buch GmbH ist ein Biotechnologie-Unternehmen und wurde 1992 gegründet. BioTeZ ist Partner der Forschung, der Pharmaindustrie und der Labordiagnostik.

  • Biodiagnostika
  • Oligonukleotide
  • Markierte Biomoleküle

Contact

BioTeZ Berlin Buch GmbH
Robert-Rössle-Strasse 10, Haus D 72
13125 Berlin - Germany

Tel: +49 30-9489-2130
Fax: +49 30-9494-509
E-Mail: info@biotez.de
www.biotez.de

Events

MedicaMeet BioTeZ at MEDICA, 12-15 Nov. 2018, Düsseldorf, hall 3, booth G54. 


10th Potsdam Days on Bioanalysis (1./2. November 2018), Potsdam; 
Dr. Janko Brand will give insights in the development projects: recoveryELISA Alirocumab, Evolocumab and PCSK9


SWISS BIOTECH DAY 2018 (3 May 2018, Basel)   Swiss_Biotech_Day
Get Information about diagnostics and biotechnological services we offer: Therapeutic Drug Monitoring, Mycotoxin and Vitamin Analysis, Individual Conjugates, ELISA Development, Oligonucleotides, Human Proteases Research, Streptavidin Coatings, Immobilization Technologies; BioTeZ will summarize outcomes of therapeutic drug monitoring studies with Omalizumab/IgE, Adalimumab/TNF and provide insights into Alirocumab, Evolocumab/PCSK9 recoveryELISA Projects.


Deutsche Biotechnologietage We present at Deutsche Biotechnologietage 18-19 April 2018